For: | Chen HT, Huang HL, Li YQ, Xu HM, Zhou YJ. Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view. World J Gastroenterol 2020; 26(16): 1901-1911 [PMID: 32390701 DOI: 10.3748/wjg.v26.i16.1901] |
---|---|
URL: | https://www.wjgnet.com/1948-5182/full/v26/i16/1901.htm |
Number | Citing Articles |
1 |
Wensheng Che, Ming Zhao, Xiaoqing Li, Chunlong Li, William C. Cho, Shan Yu. Current insights in molecular characterization of non-alcoholic fatty liver disease and treatment. Frontiers in Endocrinology 2022; 13 doi: 10.3389/fendo.2022.1002916
|
2 |
Qichen Long, Fengming Luo, Binghui Li, Ziyang Li, Zhe Guo, Zhiyang Chen, Weimin Wu, Min Hu. Gut microbiota and metabolic biomarkers in metabolic dysfunction–associated steatotic liver disease. Hepatology Communications 2024; 8(3) doi: 10.1097/HC9.0000000000000310
|
3 |
Chencheng Xie, Dina Halegoua-DeMarzio. The Role of Gut Microbiome-Targeted Therapy in Nonalcoholic Fatty Liver Disease. Current Hepatology Reports 2020; 19(4): 420 doi: 10.1007/s11901-020-00547-5
|
4 |
Ruiqi Tang, Rongrong Liu, Hua Zha, Yiwen Cheng, Zongxin Ling, Lanjuan Li. Gut microbiota induced epigenetic modifications in the non‐alcoholic fatty liver disease pathogenesis. Engineering in Life Sciences 2024; 24(5) doi: 10.1002/elsc.202300016
|
5 |
Aleksandra Bołdys, Łukasz Bułdak, Mateusz Maligłówka, Stanisław Surma, Bogusław Okopień. Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease. Medicina 2023; 59(10): 1789 doi: 10.3390/medicina59101789
|
6 |
Sanja Stojsavljevic-Shapeski, Marko Duvnjak, Lucija Virovic-Jukic, Davor Hrabar, Lea Smircic Duvnjak. New Drugs on the Block—Emerging Treatments for Nonalcoholic Steatohepatitis. Journal of Clinical and Translational Hepatology 2020; 0(000): 1 doi: 10.14218/JCTH.2020.00057
|
7 |
Carlos Pérez-Monter, Alejandro Álvarez-Arce, Natalia Nuño-Lambarri, Ivonne Escalona-Nández, Eva Juárez-Hernández, Norberto C. Chávez-Tapia, Misael Uribe, Varenka J. Barbero-Becerra. Inulin Improves Diet-Induced Hepatic Steatosis and Increases Intestinal Akkermansia Genus Level. International Journal of Molecular Sciences 2022; 23(2): 991 doi: 10.3390/ijms23020991
|
8 |
Birbal Singh, Gorakh Mal, Rajkumar Singh Kalra, Francesco Marotta. Probiotics as Live Biotherapeutics for Veterinary and Human Health, Volume 2. 2024; : 341 doi: 10.1007/978-3-031-65459-6_15
|
9 |
Aamir Bashir, Ajay Duseja, Arka De, Manu Mehta, Pramil Tiwari. Non-alcoholic fatty liver disease development: A multifactorial pathogenic phenomena. Liver Research 2022; 6(2): 72 doi: 10.1016/j.livres.2022.05.002
|
10 |
T.M. Bentsa. Nonalcoholic fatty liver disease associated with obesity and type 2 diabetes and gut dysbiosis. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) 2024; 20(2): 120 doi: 10.22141/2224-0721.20.2.2024.1373
|
11 |
Winston Hernández-Ceballos, Jacqueline Cordova-Gallardo, Nahum Mendez-Sanchez. Gut Microbiota in Metabolic-associated Fatty Liver Disease and in Other Chronic Metabolic Diseases. Journal of Clinical and Translational Hepatology 2021; 0(000): 000 doi: 10.14218/JCTH.2020.00131
|
12 |
ANA PAULA MÖRSCHBÄCHER, EMELIN PAPPEN, JOÃO ANTONIO P. HENRIQUES, CAMILLE E. GRANADA. Effects of probiotic supplementation on the gut microbiota composition of adults: a systematic review of randomized clinical trials. Anais da Academia Brasileira de Ciências 2023; 95(3) doi: 10.1590/0001-3765202320230037
|
13 |
Mona Mohamed Taha, Yasser M. Aneis, Heba Mohamed Mohamady, Alrasheedy S. A., Shereen Hamed Elsayed, Wan-Long Chuang. Effect of focused ultrasound cavitation augmented with aerobic exercise on abdominal and intrahepatic fat in patients with non-alcoholic fatty liver disease: A randomized controlled trial. PLOS ONE 2021; 16(4): e0250337 doi: 10.1371/journal.pone.0250337
|
14 |
Monika Bhardwaj, Monika Yadav. Microbiome Therapeutics. 2023; : 1 doi: 10.1016/B978-0-323-99336-4.00007-0
|
15 |
Yumeng Lei, Simin Li, Mingxin He, Zichun Ao, Jiadun Wang, Qingming Wu, Qiang Wang. Oral Pathogenic Bacteria and the Oral–Gut–Liver Axis: A New Understanding of Chronic Liver Diseases. Diagnostics 2023; 13(21): 3324 doi: 10.3390/diagnostics13213324
|
16 |
Georgia Saxami, Evangelia Kerezoudi, Christos Eliopoulos, Dimitrios Arapoglou, Adamantini Kyriacou. The Gut–Organ Axis within the Human Body: Gut Dysbiosis and the Role of Prebiotics. Life 2023; 13(10): 2023 doi: 10.3390/life13102023
|
17 |
Mingwei Tong, Xiaodan Yang, Yuyu Qiao, Ge Liu, Huihui Ge, Guangrong Huang, Yanhong Wang, Yong Yang, Weiping Fan. Serine protease inhibitor from the muscle larval Trichinella spiralis ameliorates non-alcoholic fatty liver disease in mice via anti-inflammatory properties and gut-liver crosstalk. Biomedicine & Pharmacotherapy 2024; 172: 116223 doi: 10.1016/j.biopha.2024.116223
|
18 |
Ming Yang, Xiaoqiang Qi, Nan Li, Jussuf T. Kaifi, Shiyou Chen, Andrew A. Wheeler, Eric T. Kimchi, Aaron C. Ericsson, R. Scott Rector, Kevin F. Staveley-O’Carroll, Guangfu Li. Western diet contributes to the pathogenesis of non-alcoholic steatohepatitis in male mice via remodeling gut microbiota and increasing production of 2-oleoylglycerol. Nature Communications 2023; 14(1) doi: 10.1038/s41467-023-35861-1
|
19 |
Ammar Salehi-sahlabadi, Samaneh Sadat, Sara Beigrezaei, Makan Pourmasomi, Awat Feizi, Reza Ghiasvand, Amir Hadi, Cain C. T. Clark, Maryam Miraghajani. Dietary patterns and risk of non-alcoholic fatty liver disease. BMC Gastroenterology 2021; 21(1) doi: 10.1186/s12876-021-01612-z
|
20 |
Pau Vancells Lujan, Esther Viñas Esmel, Emilio Sacanella Meseguer. Overview of Non-Alcoholic Fatty Liver Disease (NAFLD) and the Role of Sugary Food Consumption and Other Dietary Components in Its Development. Nutrients 2021; 13(5): 1442 doi: 10.3390/nu13051442
|
21 |
Qingyi Mao, Beibei Lin, Wenluo Zhang, Yu Zhang, Yu Zhang, Qian Cao, Mengque Xu. Understanding the role of ursodeoxycholic acid and gut microbiome in non-alcoholic fatty liver disease: current evidence and perspectives. Frontiers in Pharmacology 2024; 15 doi: 10.3389/fphar.2024.1371574
|
22 |
Jai J Jee, Jiyeon Lim, Sowon Park, Hong Koh, Hye Won Lee. Gut microbial community differentially characterizes patients with nonalcoholic fatty liver disease. Journal of Gastroenterology and Hepatology 2022; 37(9): 1822 doi: 10.1111/jgh.15903
|
23 |
Yuting Wang, Youwei Zheng, Lirun Kuang, Keyu Yang, Jiaji Xie, Xinde Liu, Shan Shen, Xinchao Li, Shiran Wu, Yuyi Yang, Jiafei Shi, Jialiang Wu, Yong Wang. Effects of probiotics in patients with morbid obesity undergoing bariatric surgery: a systematic review and meta-analysis. International Journal of Obesity 2023; 47(11): 1029 doi: 10.1038/s41366-023-01375-5
|
24 |
Donglei Sun, Chao Zuo, Wei Huang, Jingjing Wang, Zunzhen Zhang. Triclosan targeting of gut microbiome ameliorates hepatic steatosis in high fat diet-fed mice. The Journal of Antibiotics 2022; 75(6): 341 doi: 10.1038/s41429-022-00522-w
|
25 |
Alicia Rodríguez-Pastén, Eduardo Fernández-Martínez, Nury Pérez-Hernández, Luis E. Soria-Jasso, Raquel Cariño-Cortés. Prebiotics and Probiotics: Effects on Dyslipidemia and NAFLD/NASH and the Associated Mechanisms of Action. Current Pharmaceutical Biotechnology 2023; 24(5): 633 doi: 10.2174/1389201023666220818145350
|
26 |
Shuang Hu, Pan-pan Lian, Ying Hu, Xing-yu Zhu, Shao-wei Jiang, Qiang Ma, Liang-yun Li, Jun-fa Yang, Li Yang, Hai-yue Guo, Hong Zhou, Chen-chen Yang, Xiao-ming Meng, Jun Li, Hai-wen Li, Tao Xu, Huan Zhou. The Role of IL-35 in the Pathophysiological Processes of Liver Disease. Frontiers in Pharmacology 2021; 11 doi: 10.3389/fphar.2020.569575
|
27 |
Ting Wang, Taichi Ishikawa, Minoru Sasaki, Toshimi Chiba. Oral and Gut Microbial Dysbiosis and Non-alcoholic Fatty Liver Disease: The Central Role of Porphyromonas gingivalis. Frontiers in Medicine 2022; 9 doi: 10.3389/fmed.2022.822190
|
28 |
Guo-Ming Dong, Hang Yu, Li-Bin Pan, Shu-Rong Ma, Hui Xu, Zheng-Wei Zhang, Pei Han, Jie Fu, Xin-Yu Yang, Adili Keranmu, Hai-Tao Niu, Jian-Dong Jiang, Yan Wang. Biotransformation of Timosaponin BII into Seven Characteristic Metabolites by the Gut Microbiota. Molecules 2021; 26(13): 3861 doi: 10.3390/molecules26133861
|
29 |
Manisha Gupta, Pawan Krishan, Amarjot Kaur, Sandeep Arora, Nirupma Trehanpati, Thakur Gurjeet Singh, Onkar Bedi. Mechanistic and physiological approaches of fecal microbiota transplantation in the management of NAFLD. Inflammation Research 2021; 70(7): 765 doi: 10.1007/s00011-021-01480-z
|
30 |
Lin Zhu, Na Wang, Guang Guo, ZuoQing Fan, XinQin Shi, XianLing Ji. Male zooid extracts of Antheraea pernyi ameliorates non-alcoholic fatty liver disease and intestinal dysbacteriosis in mice induced by a high-fat diet. Frontiers in Cellular and Infection Microbiology 2022; 12 doi: 10.3389/fcimb.2022.1059647
|
31 |
Yangjun Liu, Wei Xie, Juan Li, Zbigniew Ossowski. Effects of aerobic exercise on metabolic indicators and physical performance in adult NAFLD patients: A systematic review and network meta-analysis. Medicine 2023; 102(14): e33147 doi: 10.1097/MD.0000000000033147
|
32 |
Cai-Yu Lian, Zhen-Zhen Zhai, Zi-Fa Li, Lin Wang. High fat diet-triggered non-alcoholic fatty liver disease: A review of proposed mechanisms. Chemico-Biological Interactions 2020; 330: 109199 doi: 10.1016/j.cbi.2020.109199
|
33 |
Rossella Donghia, Pasqua Letizia Pesole, Sergio Coletta, Caterina Bonfiglio, Giovanni De Pergola, Sara De Nucci, Roberta Rinaldi, Gianluigi Giannelli. Food Network Analysis in Non-Obese Patients with or without Steatosis. Nutrients 2023; 15(12): 2713 doi: 10.3390/nu15122713
|
34 |
Hang Yu, Jie Fu, Hui-Hui Guo, Li-Bin Pan, Hui Xu, Zheng-Wei Zhang, Jia-Chun Hu, Xin-Yu Yang, Hao-Jian Zhang, Meng-Meng Bu, Yuan Lin, Jian-Dong Jiang, Yan Wang. Metabolites Analysis of Anti-Myocardial Ischemia Active Components of Saussurea involucrata Based on Gut Microbiota—Drug Interaction. International Journal of Molecular Sciences 2022; 23(13): 7457 doi: 10.3390/ijms23137457
|
35 |
Ji-Shuai Wang, Jin-Chun Liu. Intestinal microbiota in the treatment of metabolically associated fatty liver disease. World Journal of Clinical Cases 2022; 10(31): 11240-11251 doi: 10.12998/wjcc.v10.i31.11240
|